 Busulfan
"Busulfan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
| Descriptor ID |
D002066
|
| MeSH Number(s) |
D02.033.455.125.125 D02.455.326.146.100.050.500.100 D02.886.645.600.055.050.510.100
|
| Concept/Terms |
Busulfan Wellcome- Busulfan Wellcome
- Wellcome, Busulfan
- Wellcome Brand of Busulfan
- Busulfan Wellcome Brand
Busulfex- Busulfex
- Orphan Brand of Busulfan
- Busulfan Orphan Brand
Myleran- Myleran
- Glaxo Wellcome Brand of Busulfan
- GlaxoSmithKline Brand of Busulfan
- Busulfan GlaxoSmithKline Brand
- Myléran
|
Below are MeSH descriptors whose meaning is more general than "Busulfan".
Below are MeSH descriptors whose meaning is more specific than "Busulfan".
This graph shows the total number of publications written about "Busulfan" by people in UAMS Profiles by year, and whether "Busulfan" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2014 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 2 | 3 | | 2006 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 1996 | 1 | 0 | 1 | | 1992 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Busulfan" by people in Profiles over the past ten years.
-
Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 Dec; 30(12):1191.e1-1191.e8.
-
Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience. Transplant Proc. 2023 Jan-Feb; 55(1):214-224.
-
Boysen G, Shimoni A, Danylesko I, Varda-Bloom N, Nagler A. A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. Rapid Commun Mass Spectrom. 2019 Nov 15; 33(21):1635-1642.
-
Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell Transplant. 2019 Dec; 28(12):1624-1631.
-
Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 04; 25(4):728-733.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|